RMND5B

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, RMND5B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RMND5B data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RMND5B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RMND5B expression acts as an unfavorable survival marker.

BLCA and UCEC are the cancer types where RMND5B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BLCAOSMedianAll0.1170.720<.00136view →
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RMND5B–BLCA (OS)

Kaplan–Meier survival curve for RMND5B mutant vs wild-type samples in BLCA.

Open the BLCA breakdown →

Exploration